Compare · RVMD vs TRXB
RVMD vs TRXB
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and TRex Bio Inc. (TRXB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and TRXB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $37.27B, about 99.3x TRXB ($375.2M).
- RVMD has been more active in the news (9 items in the past 4 weeks vs 7 for TRXB).
- RVMD has more recent analyst coverage (25 ratings vs 4 for TRXB).
- Company
- Revolution Medicines Inc.
- TRex Bio Inc.
- Price
- -
- -
- Market cap
- $37.27B
- $375.2M
- 1M return
- -8.97%
- -
- 1Y return
- +149.19%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2026
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 4
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
TRex Bio Inc.
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio's Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio's wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California.
Latest RVMD
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
- Officer Mancini Anthony sold $431,947 worth of shares (2,310 units at $186.99) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Participate in November 2026 Investor Conferences
- Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Latest TRXB
- SEC Form 10-Q filed by TRex Bio Inc.
- TRex Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Cantor Fitzgerald initiated coverage on TRex Bio, Inc.
- Stifel initiated coverage on TRex Bio, Inc. with a new price target
- Analyst initiated coverage on TRex Bio, Inc. with a new price target
- Wedbush initiated coverage on TRex Bio, Inc. with a new price target